Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference30 articles.
1. Hartmann JT. Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines. Anticancer Drugs. 2007;18:245–54. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17264755 .
2. van der Graaf WTA, Blay J-Y, Chawla SP, Kim D-W, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379:1879–86. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22595799 .
3. Rao RD, Buckner JC, Sarkaria JN. Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents. Curr Cancer Drug Targets. 2004;4:621–35. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15578919 .
4. Merimsky O, Bernstein-Molho R, Sagi-Eisenberg R. Targeting the mammalian target of rapamycin in myxoid chondrosarcoma. Anticancer Drugs. 2008;19:1019–21. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18827568 .
5. Merimsky O, Gorzalczany Y, Sagi-Eisenberg R. Molecular impacts of rapamycin-based drug combinations: combining rapamycin with gemcitabine or imatinib mesylate (Gleevec) in a human leiomyosarcoma model. Int J Oncol. 2007;31:225–32. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17549426 .
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献